UKRAINIAN BULLETIN OF PSYCHONEUROLOGY

The Scientific and Practical Journal of Medicine
ISSN 2079-0325
DOI 10.36927/2079-0325

NEUROREHABILITATION STRATEGIES IN PATIENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER

Type of Article

In the Section

Index UDK:

Abstract

The aim of this study was to summarize current evidence regarding the effectiveness of neurorehabilitation strategies in patients with Neuromyelitis Optica Spectrum Disorder (NMOSD). The study was conducted as a narrative review of scientific publications identified in the PubMed, EMBASE, Ovid, and PEDro databases over the past 10 years. Clinical studies, systematic reviews, meta-analyses, consensus documents, and clinical guidelines focusing on physical therapy, occupational therapy, gait rehabilitation, spasticity management, and the treatment of pain, fatigue, visual, cognitive, and psychoemotional impairments in NMOSD were analyzed.

The review demonstrated that early and continuous neurorehabilitation integrated into the overall patient management strategy is the most effective approach. During the acute phase, the primary objectives include prevention of complications, early mobilization, and maintenance of physical activity. In the early recovery phase, rehabilitation efforts should focus on restoring gait, muscle strength, coordination, balance, and upper limb function. In contrast, the late recovery and chronic phases emphasize occupational therapy, social reintegration, and the management of fatigue, pain, bladder dysfunction, and psychoemotional disorders. Rehabilitation outcomes are largely influenced by the serological phenotype of the disease, the severity of previous attacks, and the effectiveness of immunosuppressive therapy.

It was concluded that neurorehabilitation should be regarded as an essential component of long-term NMOSD management. Promising directions include the implementation of personalized rehabilitation programs, telerehabilitation, robotic-assisted technologies, and multidisciplinary models of care, which may contribute to improved functional independence and quality of life in affected patients.

Pages

References

  1. Bringel LAF, Lima PLGSB, Rodrigues PVF, et al. Movement Disorders in Neuromyelitis Optica Spectrum Disorder: A Systematic Review. Mov Disord Clin Pract. 2026;13(3):600-610. DOI:10.1002/mdc3.70339
  2. Chamberlain J, Siriratnam P, Huda S. Advances in the therapeutic landscape for neuromyelitis optica spectrum disorder. Expert Rev Neurother. 2025;25(10):1235-1256. DOI:10.1080/14737175.2025.2548947
  3. Abe Y, Yasui M. Aquaporin-4 in Neuromyelitis Optica Spectrum Disorders: A Target of Autoimmunity in the Central Nervous System. Biomolecules. 2022;12(4):591. Published 2022 Apr 17. DOI:10.3390/biom12040591
  4. Gholizadeh S, Exuzides A, Sinnott J, et al. Assessment of disability and disease burden in neuromyelitis optica spectrum disorders in the CIRCLES Cohort. Sci Rep. 2024;14(1):26150. Published 2024 Oct 30. DOI:10.1038/s41598-024-75013-z
  5. Meca-Lallana JE, Gómez-Ballesteros R, Pérez-Miralles F, et al. Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients’ Perspective: An Observational Cross-Sectional Study. Neurol Ther. 2022;11(3):1101-1116. DOI:10.1007/s40120-022-00356-6
  6. Bilodeau PA, Wruble Clark M, Ganguly A, et al. Real-World Efficacy and Safety of Neuromyelitis Optica Spectrum Disorder Disease-Modifying Treatments. Neurol Neuroimmunol Neuroinflamm. 2026;13(2):e200536. DOI:10.1212/NXI.0000000000200536
  7. Kozińska A, Brodowska A, Czarnecka N, Zięba N, Jamroz Wiśniewska A, Rejdak K. Exploring treatment approaches for Neuromyelitis Optica Spectrum Disorders (NMOSD). J PreClin Clin Res. 2025;19(3):99–108. DOI:10.26444/jpccr/208392
  8. Akatani R, Chihara N, Hara A, et al. Interleukin-6 Signaling Blockade Induces Regulatory Plasmablasts in Neuromyelitis Optica Spectrum Disorder. Neurol Neuroimmunol Neuroinflamm. 2024;11(4):e200266. DOI:10.1212/NXI.0000000000200266
  9. Mariotto S, Marignier R. Neuromyelitis Optica Spectrum Disorder. Continuum (Minneap Minn). 2026;32(2):513-540. DOI:10.1212/cont.0000000000001682
  10. PubMed https://pubmed.ncbi.nlm.nih.gov
  11. EMBASE https://www.embase.com
  12. Ovid® https://www.ovid.com
  13. PEDro https://pedro.org.au/ukrainian/
  14. McKeever L, Nguyen V, Peterson SJ, Gomez-Perez S, Braunschweig C. Demystifying the Search Button: A Comprehensive PubMed Search Strategy for Performing an Exhaustive Literature Review. JPEN J Parenter Enteral Nutr. 2015;39(6):622- 635. DOI:10.1177/0148607115593791
  15. Khalil H, Johns-Hayden A, Kynoch K. Guidance to including gray literature in systematic reviews-recommendations from an epidemiological study. J Clin Epidemiol. 2026;194:112222. DOI:10.1016/j.jclinepi.2026.112222
  16. Consensus AI https://consensus.app
  17. Open Evidence AI https://www.openevidence.com
  18. Alqwaifly M, Althobaiti AH, AlAibani NS, et al. Patterns of Adult Neuromyelitis Optica Spectrum Disorder Patients Compared to Multiple Sclerosis: A Systematic Review and MetaAnalysis. Cureus. 2023;15(10):e47565. Published 2023 Oct 24. DOI:10.7759/cureus.47565
  19. Ma J, Yu H, Wang H, Zhang X, Feng K. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis. J Neuroimmunol. 2022;363:577790. DOI:10.1016/j.jneuroim.2021.577790
  20. Ikeda J, Muguruma K, Ochi K, Kushitani S, Kaseda Y, Maruyama H. [Rehabilitation therapy for aquaporin-4 antibody positive neuromyelitis optica spectrum disorders]. Rinsho Shinkeigaku. 2025 Jan 29;65(1):16-21. DOI:10.5692/clinicalneurol.cn-001993. (In Japanese).
  21. Ikeda J, Kaseda Y, Namba T, Ochi M, Hayata M, Kohriyama T. Inpatient Multidisciplinary Rehabilitation Intervention Outcomes for Neuromyelitis Optica Spectrum Disorder: A Retrospective Observational Study. Prog Rehabil Med. 2016;1:20160007. Published 2016 Nov 9. DOI:10.2490/prm.20160007
  22. Wang XJ, Xia P, Yang T, Cheng K, Chen AL, Li XP. Rehabilitation and pharmacotherapy of neuromyelitis optica spectrum disorder: A case report. World J Clin Cases. 2021;9(16):3951-3959. DOI:10.12998/wjcc.v9.i16.3951
  23. Li Q, Wang B, Cheng B, et al. Efficacy and safety of rehabilitation exercise in neuromyelitis optica spectrum disorder during the acute phase: A prospective cohort study. Mult Scler Relat Disord. 2022;61:103726. DOI:10.1016/j.msard.2022.103726
  24. Otake K, Tagami T, Kido N, et al. Neuromyelitis optica with rapid respiratory failure: a case report. Acute Med Surg. 2021;8(1):e655. Published 2021 Jun 24. DOI:10.1002/ams2.655
  25. Esiason DC, Ciesinski N, Nurse CN, et al. The psychological burden of NMOSD – a mixed method study of patients and caregivers. PLoS One. 2024;19(3):e0300777. Published 2024 Mar 29. DOI:10.1371/journal.pone.0300777
  26. Kretschmer JR, Tkachenko D, Kümpfel T, et al. Worse recovery from acute attacks and faster disability accumulation highlights the unmet need for improved treatment in patients with late-onset neuromyelitis optica spectrum disorders (COPTER-LO study). Front Immunol. 2025;16:1575613. Published 2025 Apr 11. DOI:10.3389/fimmu.2025.1575613.
  27. Seok JM, Cho W, Son DH, et al. Association of subcortical structural shapes with fatigue in neuromyelitis optica spectrum disorder. Sci Rep. 2022;12(1):1579. Published 2022 Jan 28. DOI:10.1038/s41598-022-05531-1
  28. Carlisle N, Hari P, Brod S. Plegia to walking: AHSCBMT in severe NMOSD relapse. BMJ Neurol Open. 2020;2(2):e000073. Published 2020 Oct 26. DOI:10.1136/bmjno-2020-000073
  29. Li Q, Wang B, Cheng B, et al. Efficacy and safety of rehabilitation exercise in neuromyelitis optica spectrum disorder during the acute phase: A prospective cohort study. Mult Scler Relat Disord. 2022;61:103726. DOI:10.1016/j.msard.2022.103726
  30. Romano G, Lus G, Cirillo M, Coppola C, Bonavita S, Signoriello E. Double-negative NMOSD: from case report to a proposed diagnostic and therapeutic algorithm. BMC Neurol. 2025;25(1):465. Published 2025 Nov 12. DOI:10.1186/s12883-025-04326-x
  31. Carlsson O, Jonsson DI, Brundin L, Iacobaeus E. Relapses and Serious Infections in Patients with Neuromyelitis Optica Spectrum Disorder Treated with Rituximab: A Swedish SingleCenter Study. J Clin Med. 2024;13(2):355. Published 2024 Jan 8. DOI:10.3390/jcm13020355
  32. Akrivaki A, Giannopapas V, Dimitriadou E-M, Tzanetakos D, Kitsos D, Stavrogianni K, Chasiotis AK, Tsivgoulis G, Tzartos JS, Giannopoulos S. Neuropathic Pain in Neuromyelitis Optica Spectrum Disorders: Prevalence and Management Strategies – A Systematic Review and Meta-Analysis. Journal of Clinical Medicine. 2026; 15(4):1378. DOI:10.3390/jcm15041378.
  33. Luo W, Kong L, Chen H, et al. Visual disability in neuromyelitis optica spectrum disorders: prognostic prediction models. Front Immunol. 2023;14:1209323. Published 2023 Jun 7. DOI:10.3389/fimmu.2023.1209323
  34. Kümpfel T, Giglhuber K, Aktas O, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and longterm management. J Neurol. 2024;271(1):141-176. DOI:10.1007/s00415-023-11910-z. Epub 2023 Sep 7. Erratum in: J Neurol. 2024 Jun;271(6):3702-3707. DOI:10.1007/s00415-024-12288-2
  35. Yamout B, Gouider R, Al-Roughani R, et al. Consensus Recommendations for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD): The MENACTRIMS Guidelines. CNS Drugs. 2026;40(3):283-303. DOI:10.1007/ s40263-025-01260-x
  36. Wang G, Li J, Su X, et al. Global landscape of neuromyelitis optica spectrum disorder clinical trials: trends in therapies, geography, and outcomes. Front Immunol. 2026;17:1695727. Published 2026 Apr 15. DOI:10.3389/fimmu.2026.1695727